Bio-Rad Laboratories Inc (BIO) - Total Assets

Latest as of March 2026: $9.79 Billion USD

Based on the latest financial reports, Bio-Rad Laboratories Inc (BIO) holds total assets worth $9.79 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Bio-Rad Laboratories Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Bio-Rad Laboratories Inc - Total Assets Trend (1985–2025)

This chart illustrates how Bio-Rad Laboratories Inc's total assets have evolved over time, based on quarterly financial data. Explore BIO long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Bio-Rad Laboratories Inc - Asset Composition Analysis

Current Asset Composition (December 2025)

Bio-Rad Laboratories Inc's total assets of $9.79 Billion consist of 27.5% current assets and 72.5% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $529.80 Million 5.0%
Accounts Receivable $472.50 Million 4.5%
Inventory $740.70 Million 7.0%
Property, Plant & Equipment $709.90 Million 6.7%
Intangible Assets $174.30 Million 1.7%
Goodwill $579.80 Million 5.5%

Asset Composition Trend (1985–2025)

This chart illustrates how Bio-Rad Laboratories Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BIO market cap.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Bio-Rad Laboratories Inc's current assets represent 27.5% of total assets in 2025, a decrease from 75.4% in 1985.
  • Cash Position: Cash and equivalents constituted 5.0% of total assets in 2025, down from 8.4% in 1985.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 1985.
  • Asset Diversification: The largest asset category is inventory at 7.0% of total assets.

Bio-Rad Laboratories Inc Competitors by Total Assets

Key competitors of Bio-Rad Laboratories Inc based on total assets are shown below.

Company Country Total Assets
Cochlear Ltd
AU:COH
Australia AU$2.83 Billion
Shenzhen New Industries Biomedical
SHE:300832
China CN¥9.58 Billion
Jafron Biomedical Co Ltd
SHE:300529
China CN¥5.52 Billion
HOB Biotech Group Corp Ltd
SHG:688656
China CN¥912.83 Million
Polynovo Ltd
AU:PNV
Australia AU$123.37 Million
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
China CN¥3.71 Billion
Dirui Industrial Co Ltd
SHE:300396
China CN¥2.62 Billion
Emvision Medical Devices Ltd
AU:EMV
Australia AU$24.94 Million

Bio-Rad Laboratories Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.21 5.99 3.90
Quick Ratio 2.37 4.43 2.88
Cash Ratio 0.00 1.03 1.25
Working Capital $2.03 Billion $2.53 Billion $1.70 Billion

Bio-Rad Laboratories Inc - Advanced Valuation Insights

This section examines the relationship between Bio-Rad Laboratories Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 0.99
Latest Market Cap to Assets Ratio 0.58
Asset Growth Rate (YoY) 12.9%
Total Assets $10.58 Billion
Market Capitalization $6.18 Billion USD

Valuation Analysis

Below Book Valuation: The market values Bio-Rad Laboratories Inc's assets below their book value (0.58x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Bio-Rad Laboratories Inc's assets grew by 12.9% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Bio-Rad Laboratories Inc (1985–2025)

The table below shows the annual total assets of Bio-Rad Laboratories Inc from 1985 to 2025.

Year Total Assets Change
2025-12-31 $10.58 Billion +12.95%
2024-12-31 $9.36 Billion -23.86%
2023-12-31 $12.30 Billion -8.91%
2022-12-31 $13.50 Billion -24.15%
2021-12-31 $17.80 Billion +37.21%
2020-12-31 $12.97 Billion +61.98%
2019-12-31 $8.01 Billion +42.73%
2018-12-31 $5.61 Billion +31.31%
2017-12-31 $4.27 Billion +10.97%
2016-12-31 $3.85 Billion +3.80%
2015-12-31 $3.71 Billion +11.03%
2014-12-31 $3.34 Billion -1.40%
2013-12-31 $3.39 Billion -1.59%
2012-12-31 $3.44 Billion +11.20%
2011-12-31 $3.10 Billion +1.11%
2010-12-31 $3.06 Billion +20.78%
2009-12-31 $2.54 Billion +24.47%
2008-12-31 $2.04 Billion +3.33%
2007-12-31 $1.97 Billion +23.52%
2006-12-31 $1.60 Billion +11.89%
2005-12-31 $1.43 Billion +4.01%
2004-12-31 $1.37 Billion +38.18%
2003-12-31 $992.60 Million +37.73%
2002-12-31 $720.70 Million +5.36%
2001-12-31 $684.03 Million +5.84%
2000-12-31 $646.28 Million -3.38%
1999-12-31 $668.90 Million +82.11%
1998-12-31 $367.30 Million +4.38%
1997-12-31 $351.90 Million +23.52%
1996-12-31 $284.90 Million -0.07%
1995-12-31 $285.10 Million +8.12%
1994-12-31 $263.70 Million +1.46%
1993-12-31 $259.90 Million -4.69%
1992-12-31 $272.70 Million +7.74%
1991-12-31 $253.10 Million +18.71%
1990-12-31 $213.20 Million +15.62%
1989-12-31 $184.40 Million +18.74%
1988-12-31 $155.30 Million +17.65%
1987-12-31 $132.00 Million +29.92%
1986-12-31 $101.60 Million +42.10%
1985-12-31 $71.50 Million --

About Bio-Rad Laboratories Inc

NYSE:BIO USA Medical Devices
Market Cap
$6.18 Billion
Market Cap Rank
#3175 Global
#1108 in USA
Share Price
$284.67
Change (1 day)
-1.82%
52-Week Range
$235.54 - $339.75
All Time High
$825.77
About

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, pu… Read more